长效β2受体激动剂与吸入性糖皮质激素联合治疗哮喘的评估。
Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.
作者信息
Kim Dennis, Glaum Mark, Lockey Richard
机构信息
University of South Florida, James A Haley Veterans' Administration Hospital, College of Medicine, Division of Allergy and Clinical Immunology, Department of Internal Medicine, Tampa, Florida 33612, USA.
出版信息
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):933-40. doi: 10.1517/17425250903127226.
BACKGROUND
Treating asthma with a combination of inhaled corticosteroid and a long-acting beta-2-agonist is often preferred when asthma is not controlled when using a low-medium dose of an inhaled corticosteroid.
OBJECTIVE
To review the pharmacology, efficacy and safety of inhalers containing combinations of long-acting bronchodilators and inhaled corticosteroids to treat moderate-to-severe, persistent asthma.
METHODS
Using a list of keywords, we conducted a PubMed search of the literature. Data provided by the manufacturer were also reviewed.
RESULTS
Fluticasone propionate with salmeterol and budesonide with formoterol are both well tolerated, have equal clinical efficacy and have recent data affirming their safe use in diverse patient populations.
CONCLUSIONS
Combination inhalers improve asthma control in patients previously uncontrolled on inhaled corticosteroids.
背景
当使用低-中剂量吸入性糖皮质激素无法控制哮喘时，联合使用吸入性糖皮质激素和长效β2受体激动剂治疗哮喘通常是首选方法。
目的
综述含有长效支气管扩张剂和吸入性糖皮质激素组合的吸入器治疗中重度持续性哮喘的药理学、疗效和安全性。
方法
使用关键词列表在PubMed上检索文献。同时也对制造商提供的数据进行了审查。
结果
丙酸氟替卡松与沙美特罗以及布地奈德与福莫特罗的耐受性均良好，具有同等的临床疗效，且近期有数据证实它们在不同患者群体中均可安全使用。
结论
联合吸入器可改善之前使用吸入性糖皮质激素未能控制病情的患者的哮喘控制情况。
Zotero 插件